This move is archived. Current quotes and coverage live on the stock page.
Follow LABS
Medipharm Labs Corp has seen a remarkable surge in its stock price, gaining over 7% in just one trading day.
In the latest trading session, Medipharm Labs Corp (LABS.TO) closed at CA$0.07, up 7.14%. This positive momentum shows growing interest in the company as it navigates the changing cannabis industry.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$32.04M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS · as of Sep 17, 2026
Wall Street analysts forecast LABS stock price to rise 33.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+33.3% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
61.9%
Annualized
90-Day Vol
72.1%
Annualized
Trend (90d)
+29.0%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.06 – C$0.10 |
| 60 trading days | C$0.08 | C$0.06 – C$0.11 |
| 90 trading days | C$0.08 | C$0.06 – C$0.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent spike in Medipharm Labs' stock suggests renewed investor confidence, especially as the company expands internationally and prepares for future growth.
Medipharm Labs Corp gains 7.14% in one day
The stock's rise reflects a market cap of about CA$29.74 million, highlighting its position in the competitive cannabis sector.
Bull case
Medipharm Labs recently completed its first shipment to France, marking an important step in its expansion into the European medical cannabis market. This move, along with the potential benefits from U.S. cannabis rescheduling, positions the company to take advantage of new opportunities in the global cannabis market.
Bear case
Despite today's gains, Medipharm Labs still faces challenges, including a negative profit margin and the need for ongoing operational improvements to keep investors engaged.
Advertisement
Recent Developments Fueling Growth
Medipharm Labs has made significant strides by completing its first shipment to France, which is a key milestone in its growth in the European market. This strategic action, combined with the expected advantages from U.S. cannabis rescheduling, has reignited investor interest.
Market Reactions and Future Outlook
The 7.14% increase in Medipharm Labs' stock reflects positive market sentiment. However, investors should stay cautious due to the company's ongoing financial struggles, including its negative profit margin. Continuous operational improvements will be crucial for maintaining this momentum.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
